Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LIG1 | P18858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70493 | 0.84 | DAO (0.67) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL2424445 | 0.83 | DAO (0.60) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL6828047 | 0.83 | F2 (0.60) | DAOPLAUKDM4EALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL3074364 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL19987844 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL28353716 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL11598753 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1979156 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL29808747 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 | |
| SCHEMBL27562112 | 0.82 | DAO (0.64) | DAOPKMLIG1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903227-B2 | Synthesis of 2-acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-6855833-B2 | Methods for producing amino substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040225137-A1 | Methods for producing amino substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| US-6756403-B2 | 6-AMINOCHROMAN-2-YL CARBOXYLIC ACIDS AND ESTERS AS PLATELET AGGREGATION INHIBITORS; FROM PHENOL AND KETOGLUTARIC ACID; OR FROM 2-HYDROXYACETOPHENONE AND DIETHYLOXALATE; OR FROM NITROPHENOL AND DIETHYL ESTER OF MALEIC ACID | ELI LILLY AND COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20040053992-A1 | Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor | ELI LILLY AND COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| EP-1292589-A2 | METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094335-A2 | METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001094330-A2 | METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES | COR THERAPEUTICS, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001092249-A2 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092250-A2 | SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | PLA2G7, PAFAH1B2, PAFAH1B3 | DAO 315/4885PLAU 1039/4885PKM 2840/4885 |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | ACAT2, ACACA, COASY | DAO 278/4885PLAU 1886/4885PKM 2918/4885 |
| US-20040225137-A1 | Methods for producing amino substituted chromanes and intermediates thereof | PFKP, PDGFRA, TBXAS1 | DAO 6/4885PLAU 279/4885PKM 1804/4885 |
| US-20040053992-A1 | Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor | NOTUM, FAR1, CYP51A1 | DAO 105/4885PLAU 606/4885PKM 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.